“Our sales have doubled over the past 2 years. The big driver of that, I would say, over these past 2 years has been international has really been the driving factor here of success, and I expect that to continue.”

In context

“ick nuance. If you can you talk about anything that you're seeing in Europe with the Boston exit and Navitor uptake or share gains from that competitor event would be great. Robert Ford: Sure. Well, listen, we wanted to be -- our vision here is to be the leading structural heart company, global structural heart company. And the only way you can actually do that is to really have a full portfolio of products here. And obviously, I talked a little bit in my comments about mitral. We've made the investments in the tricuspid area and making the investments in the TAVR side, too. So specifically on TAVR, Navitor continues to get a lot of positive feedback from the physician to very -- it's a very compelling offering. It's an excellent [ volt ] design, easy to implant, got great clinical data. Our sales have doubled over the past 2 years. The big driver of that, I would say, over these past 2 years has been international has really been the driving factor here of success, and I expect that to continue. There's an opportunity here to accelerate that growth internationally with a competitor market exit. I know the team is all over that. And with the upcoming CE mark that we have planned for Navitor to have low and intermediate risk label expansion. It couldn't come at a perfect time to be quite honest with you. So I expect that to continue and accelerate for us, Josh. And then we're building our position here in the United States. Right now, we're in about 20% of the centers in the United States. And the way to expand our position here is we got to be in more centers. And the way to do that is you need more clinical people, you need more feet on the street. And that's what we're doing. So we've actually -- we will be doubling the size of our team -- and I'd say, putting ourselves in the r”